MX2012002153A - Uso de mimotopos de epitopos de alfa-synucleina para tratar enfermedades de cuerpos de lewy. - Google Patents

Uso de mimotopos de epitopos de alfa-synucleina para tratar enfermedades de cuerpos de lewy.

Info

Publication number
MX2012002153A
MX2012002153A MX2012002153A MX2012002153A MX2012002153A MX 2012002153 A MX2012002153 A MX 2012002153A MX 2012002153 A MX2012002153 A MX 2012002153A MX 2012002153 A MX2012002153 A MX 2012002153A MX 2012002153 A MX2012002153 A MX 2012002153A
Authority
MX
Mexico
Prior art keywords
mimotopes
alpha
lewy body
body diseases
treating lewy
Prior art date
Application number
MX2012002153A
Other languages
English (en)
Inventor
Markus Mandler
Radmila Santic
Harald Weninger
Christian Lahsnig
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of MX2012002153A publication Critical patent/MX2012002153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a péptidos o polipéptidos para producir medicamentos para prevenir y/o tratar sinucleinopatías.
MX2012002153A 2009-08-21 2010-08-20 Uso de mimotopos de epitopos de alfa-synucleina para tratar enfermedades de cuerpos de lewy. MX2012002153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0132409A AT508638B1 (de) 2009-08-21 2009-08-21 Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PCT/AT2010/000303 WO2011020133A1 (en) 2009-08-21 2010-08-20 Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases

Publications (1)

Publication Number Publication Date
MX2012002153A true MX2012002153A (es) 2012-03-14

Family

ID=42940852

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002153A MX2012002153A (es) 2009-08-21 2010-08-20 Uso de mimotopos de epitopos de alfa-synucleina para tratar enfermedades de cuerpos de lewy.

Country Status (21)

Country Link
US (1) US8828942B2 (es)
EP (1) EP2467153B1 (es)
JP (2) JP2013502379A (es)
KR (2) KR20140141651A (es)
CN (1) CN102596224B (es)
AT (1) AT508638B1 (es)
AU (1) AU2010283948B2 (es)
BR (1) BR112012003800A2 (es)
CA (1) CA2771429A1 (es)
CY (1) CY1117582T1 (es)
DK (1) DK2467153T3 (es)
ES (1) ES2573662T3 (es)
HR (1) HRP20160594T1 (es)
HU (1) HUE027563T2 (es)
IL (1) IL218207A0 (es)
MX (1) MX2012002153A (es)
PL (1) PL2467153T3 (es)
PT (1) PT2467153E (es)
RU (1) RU2532351C2 (es)
SI (1) SI2467153T1 (es)
WO (1) WO2011020133A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
SI3071597T1 (sl) 2013-11-21 2020-11-30 F. Hoffmann-La Roche Ag Anti alfa-sinukleinska protitelesa in postopki uporabe
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
KR101726549B1 (ko) 2016-06-29 2017-04-12 정상문 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식
KR102087494B1 (ko) 2018-03-15 2020-03-10 정상문 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법
EP3897711A1 (en) 2018-12-20 2021-10-27 Saiba AG Virus-like particles of cmv modified by fusion
US20230242601A1 (en) * 2020-07-29 2023-08-03 Tohoku University Peptide used to prevent or treat synucleinopathy
IL300364A (en) 2020-08-04 2023-04-01 Ac Immune Sa immunogenic substances
BR112023020640A2 (pt) 2021-04-12 2023-12-05 Saiba AG Partículas similares a vírus de bacteriófago ap205 modificadas
TW202306966A (zh) * 2021-06-18 2023-02-16 日商住友製藥股份有限公司 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物
CR20240371A (es) 2022-02-09 2024-10-16 Ac Immune Sa Vacunas terapéuticas anti-alfa-sinucleína
CA3243638A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg CONJUGATED CONSISTING OF OR COMPRISING AT LEAST ONE SS-GLUCANE OR ONE MANNANE
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007325595A (ja) * 2000-12-22 2007-12-20 Locomogene Inc 滑膜細胞タンパク質
US7479482B2 (en) * 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
HUE035044T2 (en) 2003-05-19 2018-05-02 Prothena Biosciences Ltd Truncated fragments of alpha-synuclein in Lewy-body disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2004113535A1 (ja) 2003-06-22 2004-12-29 Koji Sode 凝集抑制作用を有するシヌクレイン変異体
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
CN101052417A (zh) 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
MX2007001679A (es) * 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
ES2551604T3 (es) * 2005-12-12 2015-11-20 Ac Immune S.A. Vacuna terapéutica
CA2746778C (en) * 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies

Also Published As

Publication number Publication date
AT508638A1 (de) 2011-03-15
EP2467153A1 (en) 2012-06-27
JP2013502379A (ja) 2013-01-24
JP2015038078A (ja) 2015-02-26
CN102596224A (zh) 2012-07-18
HRP20160594T1 (hr) 2016-07-29
IL218207A0 (en) 2012-04-30
PL2467153T3 (pl) 2016-09-30
CA2771429A1 (en) 2011-02-24
RU2532351C2 (ru) 2014-11-10
WO2011020133A1 (en) 2011-02-24
KR101517447B1 (ko) 2015-05-28
PT2467153E (pt) 2016-06-08
EP2467153B1 (en) 2016-03-02
HK1170658A1 (zh) 2013-03-08
ES2573662T3 (es) 2016-06-09
HUE027563T2 (en) 2016-10-28
BR112012003800A2 (pt) 2016-11-22
AU2010283948B2 (en) 2015-01-22
AU2010283948A1 (en) 2012-03-29
AT508638B1 (de) 2011-08-15
SI2467153T1 (sl) 2016-07-29
KR20140141651A (ko) 2014-12-10
US8828942B2 (en) 2014-09-09
RU2012110582A (ru) 2013-09-27
DK2467153T3 (en) 2016-06-06
US20120156234A1 (en) 2012-06-21
CN102596224B (zh) 2015-12-09
JP5901714B2 (ja) 2016-04-13
KR20120059562A (ko) 2012-06-08
CY1117582T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2012002153A (es) Uso de mimotopos de epitopos de alfa-synucleina para tratar enfermedades de cuerpos de lewy.
PH12014501685A1 (en) Humanized antibodies that recognize alpha-synuclein
NZ611108A (en) Methods of treating fgf21-associated disorders
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
HUS2400027I1 (hu) Rekombináns humán G-CSF dimer és alkalmazása, neurológiai betegségek kezelésében
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
IL247183B (en) Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases
IL213407A (en) Use of combinations of drug factors to prepare combination therapy drugs
MX2013004726A (es) Anticuerpos dkk1 y metodos de uso.
PH12012502393A1 (en) Forms of rifaximin and uses thereof
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
IL215467A0 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
SG11201912195TA (en) Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
NZ594347A (en) Antibodies against human tweak and uses thereof
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MY184647A (en) Arylated camphenes, processes for their preparation and uses thereof
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
UA104714C2 (ru) Выделенный полинуклеотид brachyspira hyodysenteriae, кодирующий полипептид, и его применение
CA192160S (en) Vaporizer body
MY169961A (en) Therapeutic use of protein-polymer conjugates
SG138488A1 (en) Novel polypeptides for anti-viral treatment

Legal Events

Date Code Title Description
FG Grant or registration